Updates in diagnosis and treatment of inflammatory myofibroblastic tumor in children

References:

[1] Li YP,Han WW,He LJ,et al.Inflammatory myofibroblastic tumor after treatment of Wilms tumor in a 6-year-old boy:a case report and literature review[J].Urology,2021,149:e25-e28.DOI:10.1016/j.urology.2020.11.012.
[2] Lindberg MR,Cassarino DS,Gardner J,et al.Soft tissue tumors:a practical and comprehensive guide to sarcomas and benign neoplasms[M].Diagnostic Pathology-Soft Tissue Tumors,2019,88/99:114-119.
[3] Lahcen K,Wilfried C,Abibou N,et al.Inflammatory maxillary myofibroblastic tumor:a case report[J].Saudi J Med Pharm Sci,2020,6(7):480-484.DOI:10.36348/sjmps.2020.v06i07.001.
[4] Zhao JL,Han DJ,Gao MZ,et al.Inflammatory myofibroblastic tumor of the neck with thyroid invasion:a case report and literature review[J].Gland Surg,2020,9(4):1042-1047.DOI:10.21037/gs-20-355.
[5] Filips A,Maurer MH,Montani M,et al.Inflammatory myofibroblastic tumor of the liver:a case report and review of literature[J].World J Hepatol,2020,12(4):170-183.DOI:10.4254/wjh.v12.i4.170.
[6] Armstrong V,Khazeni K,Rosenberg A,et al.Inflammatory pseudotumor secondary to urachal cyst:a challenging clinical case report[J].Int J Surg Case Rep,2020,66:360-364.DOI:10.1016/j.ijscr.2019.12.029.
[7] Zarei S,Abdul-Karim FW,Chase DM,et al.Uterine inflammatory myofibroblastic tumor showing an atypical ALK signal pattern by FISH and DES-ALK fusion by RNA sequencing:a case report[J].Int J Gynecol Pathol,2020,39(2):152-156.DOI:10.1097/PGP.0000000000000588.
[8] Mamone G,Di Piazza A,Carollo V,et al.Imaging of primary malignant tumors in non-cirrhotic liver[J].Diagn Interv Imaging,2020,101(9):519-535.DOI:10.1016/j.diii.2020.01.010.
[9] Lee JC,Li CF,Huang HY,et al.ALK oncoproteins in atypical inflammatory myofibroblastic tumours:novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma[J].J Pathol,2017,241(3):316-323.DOI:10.1002/path.4836.
[10] Coffin CM,Hornick JL,Fletcher CDM.Inflammatory myofibroblastic tumor:comparison of clinicopathologic,histologic,and immunohistochemical features including ALK expression in atypical and aggressive cases[J].Am J Surg Pathol,2007,31(4):509-520.DOI:10.1097/01.pas.0000213393.57322.c7.
[11] Bennett JA,Nardi V,Rouzbahman M,et al.Inflammatory myofibroblastic tumor of the uterus:a clinicopathological,immunohistochemical,and molecular analysis of 13 cases highlighting their broad morphologic spectrum[J].Mod Pathol,2017,30(10):1489-1503.DOI:10.1038/modpathol.2017.69.
[12] Devereaux KA,Fitzpatrick MB,Hartinger S,et al.Pregnancy-associated inflammatory myofibroblastic tumors of the uterus are clinically distinct and highly enriched for TIMP3-ALK and THBS1-ALK fusions[J].Am J Surg Pathol,2020,44(7):970-981.DOI:10.1097/PAS.0000000000001481.
[13] 王一真,任素珍.儿童炎性肌纤维母细胞瘤11例临床病理分析[J].诊断病理学杂志,2012,19(5):355-357.DOI:10.3969/j.issn.1007-8096.2012.05.009. Wang YZ,Ren SZ.Inflammatory myofibroblastic tumor in children:a clinicopathologic study of 11 cases[J].Chin J Diagn Pathol,2012,19(5):355-357.DOI:10.3969/j.issn.1007-8096.2012.05.009.
[14] Siemion K,Reszec-Gielazyn J,Kisluk J,et al.What do we know about inflammatory myofibroblastic tumors?-A systematic review[J].Adv Med Sci,2022,67(1):129-138.DOI:10.1016/j.advms.2022.02.002.
[15] Bennett JA,Croce S,Pesci A,et al.Inflammatory myofibroblastic tumor of the uterus:an immunohistochemical study of 23 cases[J].Am J Surg Pathol,2020,44(11):1441-1449.DOI:10.1097/PAS.0000000000001525.
[16] Dalton BGA,Thomas PG,Sharp NE,et al.Inflammatory myofibroblastic tumors in children[J].J Pediatr Surg,2016,51(4):541-544.DOI:10.1016/j.jpedsurg.2015.11.015.
[17] Pulford K,Morris SW,Mason DY.Anaplastic lymphoma kinase proteins and malignancy[J].Curr Opin Hematol,2001,8(4):231-236.DOI:10.1097/00062752-200107000-00009.
[18] Chan JK,Cheuk W,Shimizu M.Anaplastic lymphoma kinase expression in inflammatory pseudotumors[J].Am J Surg Pathol,2001,25(6):761-768.DOI:10.1097/00000478-200106000-00007.
[19] Debelenko LV,Arthur DC,Pack SD,et al.Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor[J].Lab Invest,2003,83(9):1255-1265.DOI:10.1097/01.lab.0000088856.49388.ea.
[20] Ma ZG,Hill DA,Collins MH,et al.Fusion of ALK to the ran-binding protein 2(RANBP2) gene in inflammatory myofibroblastic tumor[J].Genes Chromosomes Cancer,2003,37(1):98-105.DOI:10.1002/gcc.10177.
[21] Bridge JA,Kanamori M,Ma ZG,et al.Fusion of the ALK gene to the clathrin heavy chain gene,CLTC,in inflammatory myofibroblastic tumor[J].Am J Pathol,2001,159(2):411-415.DOI:10.1016/S0002-9440(10)61711-7.
[22] Mano H.ALKoma:a cancer subtype with a shared target[J].Cancer Discov,2012,2(6):495-502.DOI:10.1158/2159-8290.CD-12-0009.
[23] Voena C,Chiarle R.The battle against ALK resistance:successes and setbacks[J].Expert Opin Investig Drugs,2012,21(12):1751-1754.DOI:10.1517/13543784.2012.717930.
[24] Kerr DA,Thompson LDR,Tafe LJ,et al.Clinicopathologic and genomic characterization of inflammatory myofibroblastic tumors of the head and neck:highlighting a novel fusion and potential diagnostic pitfall[J].Am J Surg Pathol,2021,45(12):1707-1719.DOI:10.1097/PAS.0000000000001735.
[25] WHO Classification of Tumours Editorial Board.WHO classification of tumours:soft tissue and bone tumours[M].5th ed.Geneva:World Health Organization,2020:109-111.
[26] Doski JJ,Priebe CJ Jr,Driessnack M,et al.Corticosteroids in the management of unresected plasma cell granuloma (inflammatory pseudotumor) of the lung[J].J Pediatr Surg,1991,26(9):1064-1066.DOI:10.1016/0022-3468(91)90674-i.
[27] Panigada S,Sacco O,Girosi D,et al.Corticosteroids may favor proliferation of thoracic inflammatory myofibroblastic tumors[J].Pediatr Pulmonol,2014,49(3):E109-E111.DOI:10.1002/ppul.22977.
[28] Germanidis G,Xanthakis I,Tsitouridis I,et al.Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment[J].Dig Dis Sci,2005,50(2):262-265.DOI:10.1007/s10620-005-1593-1.
[29] Grünholz D,Appiani F,Abarca C,et al.Peritoneal myofibroblastic tumor successfully treated with infliximab:report of one case[J].Rev Med Chil,2015,143(7):943-947.DOI:10.4067/s0034-98872015000700017.
[30] Casanova M,Brennan B,Alaggio R,et al.Inflammatory myofibroblastic tumor:the experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)[J].Eur J Cancer,2020,127:123-129.DOI:10.1016/j.ejca.2019.12.021.
[31] Butrynski JE,D’Adamo DR,Hornick JL,et al.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor[J].N Engl J Med,2010,363(18):1727-1733.DOI:10.1056/NEJMoa1007056.
[32] Pearson ADJ,Barry E,Mossé YP,et al.Second paediatric strategy forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies:ACCELERATE in collaboration with the European medicines agency with the participation of the food and drug administration[J].Eur J Cancer,2021,157:198-213.DOI:10.1016/j.ejca.2021.08.022.
[33] Sch?ffski P,Sufliarsky J,Gelderblom H,et al.Crizotinib in patients with advanced,inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE):a multicentre,single-drug,prospective,non-randomised phase 2 trial[J].Lancet Respir Med,2018,6(6):431-441.DOI:10.1016/S2213-2600(18)30116-4.
[34] Mossé YP,Voss SD,Lim MS,et al.Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor:a children’s oncology group study[J].J Clin Oncol,2017,35(28):3215-3221.DOI:10.1200/JCO.2017.73.4830.
[35] Trahair T,Gifford AJ,Fordham A,et al.Crizotinib and surgery for long-term disease control in children and adolescents with ALK-positive inflammatory myofibroblastic tumors[J].JCO Precis Oncol,2019,3:1-11.DOI:10.1200/PO.18.00297.
[36] Yuan C,Ma MJ,Parker JV,et al.Metastatic anaplastic lymphoma kinase-1(ALK-1)-rearranged inflammatory myofibroblastic sarcoma to the brain with leptomeningeal involvement:favorable response to serial ALK inhibitors:a case report[J].Am J Case Rep,2017,18:799-804.DOI:10.12659/ajcr.903698.
[37] Mansfield AS,Murphy SJ,Harris FR,et al.Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib[J].Ann Oncol,2016,27(11):2111-2117.DOI:10.1093/annonc/mdw405.
[38] Mittal A,Gupta A,Rastogi S,et al.Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour[J].Ecancermedicalscience,2021,15:1215.DOI:10.3332/ecancer.2021.1215.
[39] Kong XT,Pan PC,Sun HY,et al.Drug discovery targeting anaplastic lymphoma kinase (ALK)[J].J Med Chem,2019,62(24):10927-10954.DOI:10.1021/acs.jmedchem.9b00446.
[40] Liu DZ,Offin M,Harnicar S,et al.Entrectinib:an orally available,selective tyrosine kinase inhibitor for the treatment of NTRK,ROS1,and ALK fusion-positive solid tumors[J].Ther Clin Risk Manag,2018,14:1247-1252.DOI:10.2147/TCRM.S147381.
[41] Shankar A,Kurzawinski T,Ross E,et al.Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma[J].Eur J Cancer,2021,158:38-46.DOI:10.1016/j.ejca.2021.09.012.
[42] Cha YJ,Shim HS.PD-L1 expression and CD8+tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors[J].Oncotarget,2017,8(52):89465-89474.DOI:10.18632/oncotarget.20948.
[43] Cottrell TR,Duong AT,Gocke CD,et al.PD-L1 expression in inflammatory myofibroblastic tumors[J].Mod Pathol,2018,31(7):1155-1163.DOI:10.1038/s41379-018-0034-6.
[44] Fordham AM,Xie JH,Gifford AJ,et al.CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma[J].Br J Cancer,2020,123(7):1101-1113.DOI:10.1038/s41416-020-0996-2.